CompletedPhase 4NCT01088750
Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Christine Mauz-Körholz
- Principal Investigator
- Dieter Koerholz, MDUniversitaetsklinikum Giessen und Marburg
- Intervention
- cyclophosphamide(drug)
- Enrollment
- 225 target
- Eligibility
- 17 years · All sexes
- Timeline
- 2009 – 2023
Study locations (1)
- Universitaetsklinikum Giessen-Marburg, Giessen, Germany
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany) · Euronet Worldwide
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01088750 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →